Microba Life Sciences (ASX:MAP) Total Receivables: A$2.85 Mil (As of Dec. 2025)


What is Microba Life Sciences Total Receivables?

Microba Life Sciences ASX:MAP +19.44% Total Receivables is A$2.85 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Microba Life Sciences's Total Receivables for the quarter that ended in Dec. 2025 was A$2.85 Mil.

Microba Life Sciences Total Receivables Related Terms

Microba Life Sciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Total Receivables Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Receivables
3.42 7.24 8.10 4.11

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only 12.41 8.10 2.16 4.11 2.85

Microba Life Sciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$2.85 Mil mean?
Microba Life Sciences (ASX:MAP) has a Total Receivables of A$2.85 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Microba Life Sciences and its competitors.
Is Microba Life Sciences' Total Receivables too high?
Microba Life Sciences' current Total Receivables is A$2.85 Mil.
How does Microba Life Sciences' Total Receivables compare to TMO and DHR?
Microba Life Sciences' Total Receivables of A$2.85 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Diagnostics & Research company?
A good Total Receivables depends on the Medical Diagnostics & Research industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current Total Receivables is A$2.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 82.8% below its estimated fair value. The current Total Receivables is A$2.85 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Total Receivables is A$2.85 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.